Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy

(2020) Imtiaz A. Samjoo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Ofatumumab versus Teriflunomide in Multiple Sclerosis

(2020) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis

(2019) Rachael McCool et al.   Multiple Sclerosis and Related Disorders

Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis

(2018) Rosa C. Lucchetta et al.   CNS DRUGS

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

(2018) Amit Bar-Or et al.   NEUROLOGY

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis

(2018) Chris Cameron et al.   Journal of Comparative Effectiveness Research

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

(2017) GJ Melendez-Torres et al.   HEALTH TECHNOLOGY ASSESSMENT

The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis

(2017) Chris Cameron et al.   MEDICAL DECISION MAKING

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis

(2017) Eline Huisman et al.   BMJ Open

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis

(2016) Emer Fogarty et al.   Multiple Sclerosis and Related Disorders

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis

(2015) Keith Tolley et al.   PLoS One

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

(2015) Georgios Tsivgoulis et al.   PLoS One

A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer

(2014) Shannon Cope et al.   BMC Medicine

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers

(2013) Jeroen P Jansen et al.   BMC Medicine

Onset of secondary progressive phase and long-term evolution of multiple sclerosis

(2013) A. Scalfari et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effects of Interferon �-1a and Interferon �-1b Monotherapies on Selected Serum Cytokines and Nitrite Levels in Patients with Relapsing-Remitting Multiple Sclerosis: A 3-Year Longitudinal Study

(2013) Adam Stepien et al.   NEUROIMMUNOMODULATION

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

(2012) Georgia Salanti   Research Synthesis Methods

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis

(2011) M Calabrese et al.   Multiple Sclerosis Journal

Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

(2011) David C. Hoaglin et al.   VALUE IN HEALTH

Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

(2011) Jeroen P. Jansen et al.   VALUE IN HEALTH

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Ofatumumab

(2010) Bodi Zhang   mAbs

A basic introduction to fixed-effect and random-effects models for meta-analysis

(2010) Michael Borenstein et al.   Research Synthesis Methods

Natural history of secondary-progressive multiple sclerosis

(2008) Helen Tremlett et al.   Multiple Sclerosis Journal

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE